MINI FUTURE LONG - ZEALAND PHARMA | Market Closed - Börse Stuttgart 02:00:41 2024-06-07 pm EDT | ||
| 7.41 EUR | 0.00% |
|
| Current month | +3.99% | ||
| 1 month | +2.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 7.56 | +2.02% |
| 24-06-06 | 7.41 | +7.70% |
| 24-06-05 | 6.88 | +0.15% |
| 24-06-04 | 6.87 | -6.66% |
| 24-06-03 | 7.36 | +1.24% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 02:00 pm EDT
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MB1FVD |
| ISIN | DE000MB1FVD9 |
| Date issued | 2022-12-15 |
| Strike | 99.69 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.41 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.8 € |
|---|---|
| Lowest since issue | 1.38 € |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
650
DKK
Average target price
790.9
DKK
Spread / Average Target
+21.67%
- Stock Market
- Certificates
- Certificat
